Michael Mulligan
Advisor: Paul Hergenrother
Cohort: 2020

The advent of large chemical libraries and high throughput screening has enabled the rapid identification of drug candidates for cancer allowing for more drug personalization than previously possible. The specificity granted by this approach is often necessary to selectively differentiate cancer cells from healthy cells. My research is focused on identifying small molecules with anticancer activity, and performing subsequent SAR studies which simultaneously inform protein target identification campaigns as well as identify analogs with promising therapeutic potential. This approach seeks to pair translational relevance with the exploration of fundamental chemical biology through the elucidation of novel protein targets/pathways.